Available Until 2/26/2025

Clinical Case Studies: Best Practices for the Use of Pharmacotherapy in Obesity

ACPE Activity Number:   0204-0000-24-400-H01-P
Content Release Date: February 26, 2024
Expiration Date: February 26, 2025
Activity Type: Application-based   
CE Credits: 1 contact hour (0.10 CEUs)
Activity Fee: Free

Activity Overview

There are various treatment options for patients with obesity that differ in dosing, titration, administration, percent change in body weight, improvement in cardiometabolic risk factors, management of comorbidities, and adverse events. As obesity continues to be an epidemic in the United States, pharmacists should understand how to choose an appropriate agent for obesity based on the individual patient’s comorbidities and goals of therapy.

The activity will illustrate the pharmacist’s role within the interprofessional care team, opportunities to improve access to medications for weight loss, and methods to identify patients who would benefit from a medication for obesity. This educational activity will also use clinical case studies to promote best practices in obesity treatment and develop a patient-centered treatment plan.

*Please note, this activity was presented live as a live webinar on 1/25/2024. You can only claim credit once for this activity; live or home study

More in this Series:

PodcastWhat You Need to Know About Obesity and Newer Treatments – Part 1

What You Need to Know About Obesity and Newer Treatments – Part 2

On-Demand Activity: Exploring Strategies for Combating Weight Loss: Unveiling Safe and Sustainable Long-Term Treatment Approaches

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, and ambulatory clinics who care for or are interested in the care of patients with obesity.

At the conclusion of this activity, participants should be able to

  • Apply strategies for individualizing pharmacotherapy in obesity leading to optimal outcomes and reduction of comorbidities.
  • Evaluate opportunities to increase access to weight loss medications, including glucagon-like peptide 1 receptor agonists through pharmacist collaborative practice agreements. 

Jennifer N. Clements, PharmD, BCPS, BCACP, BC-ADM, CDCES, FCCP, FADCES, Activity Chair
Clinical Professor and Director of Pharmacy Education
University of South Carolina College of Pharmacy
Greenville, South Carolina

More information on Jennifer N. Clements

Dr. Clements is a clinical professor and director of Pharmacy Education with the University of South Carolina, College of Pharmacy at the School of Medicine – Greenville Campus. Dr. Clements earned her PharmD from Campbell University in 2006 and completed a primary care pharmacy practice residency in 2007 at the Ralph H. Johnson VA Medical Center in Charleston, South Carolina. She is a board-certified pharmacotherapy specialist, board-certified ambulatory care pharmacist, certified diabetes care and education specialist, and board certified in advanced diabetes management. Dr. Clements has authored numerous publications and presentations related to diabetes and obesity pharmacotherapy.


Director, Education & Training in Diabetes Technology
Cleveland Clinic
Cleveland, Ohio

More information on Dana Isaacs

Dr. Isaacs is an endocrine clinical pharmacy specialist and the director of Education and Training in Diabetes Technology at the Cleveland Clinic. Dr. Isaacs serves in leadership roles for several pharmacy and diabetes organizations. She served on the ADA Professional Practice Committee for 2020-2023, the committee that updates the ADA Standards of Care. She is a national board member of the Association of Diabetes Care and Education Specialists. Dr. Isaacs was awarded the Ohio Pharmacists Association Under 40 Award in 2019 and was the 2020 ADCES Diabetes Care and Education Specialist of the Year. In 2022, she was inducted into the Southern Illinois University Edwardsville Hall of Fame for her far-reaching contributions in patient care.

Jeffery S. Vender, MD, MCCM, MBA is the Emeritus, Harris Family Foundation Chairman of the Department of Anesthesiology at NorthShore University Health System in Evanston, Illinois and a Clinical Professor at the University of Chicago Pritzker School Of Medicine in Chicago, Illinois. He is a past member of the NorthShore University Health System Faculty Practice Associates Board of Directors, Past Chair of the Medical Executive Committee for the Professional Staff at NorthShore and previously served on Northshore’s Board of Directors. Dr. Vender served as Chair of Anesthesia from 1990-2015 and received an appointment of adjunct Professor of Biomedical Engineering at Northwestern University. He served as the Director of the Critical Care Services at Evanston Hospital from 1987-2000 and the Interim Chairman at Northwestern University Department of Anesthesiology from July 1999 until October 2000. Dr. Vender has participated and Chaired numerous state and national committees of various medical organizations, edited several medical texts, has published over 135 articles and book chapters and has been an invited lecturer at over 250 national and international meetings on topics of anesthesiology, critical care, organizational change, and leadership. In addition, Dr. Vender serves as an editor and/or reviewer for many medical journals.

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

  • Jennifer N. Clements: Novo Nordisk – Speaker’s bureau, Xeris Pharmaceuticals – Consultant, Embecta – Advisory board, Lilly - Speaker’s bureau
  • Diana Isaacs: Dexcom – Speaker’s bureau , Abbott – Speaker’s bureau, Novo Nordisk – Speaker’s bureau, Lilly - Speaker’s bureau, Sanofi – Consultant

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Claim CE Within 60 Days

To receive CE credit, complete the steps below within 60 days of completing the activity.

  1.        View the entire presentation and answer all polling questions.
  2.        Click "Complete Activity" on last slide then complete the evaluation to claim credit. 
  3.        Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

Provided by ASHP

Supported by an educational grant from Novo Nordisk Inc.